Trials / Conditions / Leukemia, Lymphocytic, Chronic

Leukemia, Lymphocytic, Chronic

28 registered clinical trials studyying Leukemia, Lymphocytic, Chronic — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Unknown	Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic NCT05154474	Weprom	—
Completed	Intermittent Fasting and CLL/SLL NCT04626843	Eleah Stringer	Phase 1
Completed	Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL NCT04030195	Precision BioSciences, Inc.	Phase 1 / Phase 2
Completed	Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Sma NCT03204188	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2
Completed	Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL NCT02758665	University of Ulm	Phase 2
Terminated	A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors NCT02440685	Asana BioSciences	Phase 1 / Phase 2
Terminated	MSC and HSC Coinfusion in Mismatched Minitransplants NCT01045382	University of Liege	Phase 2
Terminated	Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical NCT01050946	Medical College of Wisconsin	Phase 2
Terminated	EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT00636155	David Rizzieri	Phase 2
Completed	Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL NCT00546793	Gilead Sciences	Phase 1 / Phase 2
Completed	Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients NCT00562224	Pharmacyclics LLC.	Phase 1
Completed	Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising NCT00464633	Sanofi	Phase 2
Terminated	Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor NCT00393380	The Emmes Company, LLC	Phase 2
Terminated	Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL) NCT00290407	University of Louisville	Phase 2
Completed	A Safety Study in Patients With Chronic Lymphocytic Leukemia NCT00283101	Seagen Inc.	Phase 1 / Phase 2
Completed	Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukem NCT00289549	BioCryst Pharmaceuticals	Phase 2
Recruiting	Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies NCT00131014	Dana-Farber Cancer Institute	—
Terminated	A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia NCT00083473	Titan Pharmaceuticals	Phase 2
Terminated	Post Transplant Donor Lymphocyte Infusion NCT00167180	Masonic Cancer Center, University of Minnesota	Phase 2
Completed	Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) NCT00055146	Eisai Inc.	Phase 2
Terminated	A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach NCT00038415	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Terminated	Stem Cell Transplant for Hematological Malignancy NCT00176930	Masonic Cancer Center, University of Minnesota	N/A
Terminated	Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies NCT00038883	M.D. Anderson Cancer Center	N/A
Completed	Clofarabine in Chronic Lymphocytic Leukemia NCT00028418	M.D. Anderson Cancer Center	Phase 1
Completed	Phase III Study Treatment of CLL B and C NCT00535912	French Innovative Leukemia Organisation	Phase 3
Completed	Transplantation for Patients With Chronic Lymphocytic Leukemia NCT00186303	Stanford University	N/A
Completed	Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia NCT00270049	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 2
Terminated	A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL) NCT00076401	Pharmacyclics LLC.	Phase 2